Compare KR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | EW |
|---|---|---|
| Founded | 1883 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8B | 45.5B |
| IPO Year | N/A | 2000 |
| Metric | KR | EW |
|---|---|---|
| Price | $62.55 | $85.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | $73.46 | ★ $95.83 |
| AVG Volume (30 Days) | ★ 7.3M | 3.4M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.16 | ★ 2.33 |
| Revenue | ★ $147,225,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $4.12 | $14.26 |
| Revenue Next Year | $2.81 | $9.77 |
| P/E Ratio | $54.11 | ★ $36.40 |
| Revenue Growth | N/A | ★ 10.60 |
| 52 Week Low | $58.12 | $65.94 |
| 52 Week High | $74.90 | $87.89 |
| Indicator | KR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 56.96 |
| Support Level | $61.97 | $84.64 |
| Resistance Level | $63.90 | $86.19 |
| Average True Range (ATR) | 1.37 | 1.70 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 23.08 | 65.56 |
Kroger is one of the largest grocery retailers in the United States with about 2,700 stores across a portfolio of over 20 supermarket banners. The company boasts an ingrained presence in US communities, citing that it is a top-two grocer in most of its major market areas. Over one fourth of Kroger's roughly $110 billion in nonperishable and fresh food sales (about 75% of revenue) stems from its private-label portfolio, of which the company manufactures about 30% of units via its own food production plants. The company also operates fuel stations and pharmacies at 60% and 80% of its locations, respectively.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.